Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.43 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 2/20 | 0.41 |
| ▸ | KRAS | P01116 | 4/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16636606 | 0.88 | KRAS (0.53) | SMARCA2SMARCA4PBRM1GBA1KIT | |
| SCHEMBL29765860 | 0.88 | KRAS (0.53) | SMARCA2SMARCA4PBRM1GBA1KIT | |
| SCHEMBL20109703 | 0.83 | KRAS (0.44) | SMARCA2SMARCA4PBRM1GBA1KIT | |
| SCHEMBL25990876 | 0.78 | GBA1 (0.47) | SMARCA2SMARCA4PBRM1GBA1KIT | |
| SCHEMBL20858007 | 0.76 | TLR9 (0.41) | SMARCA2SMARCA4PBRM1GBA1KIT | |
| SCHEMBL16636866 | 0.75 | KRAS (0.55) | GBA1KRAS | |
| SCHEMBL16637457 | 0.75 | KCNH2 (0.40) | SMARCA2SMARCA4PBRM1GBA1KIT | |
| SCHEMBL29765694 | 0.75 | KCNH2 (0.40) | SMARCA2SMARCA4PBRM1GBA1KIT | |
| SCHEMBL21458459 | 0.74 | KRAS (0.51) | GBA1KRAS | |
| SCHEMBL21458461 | 0.74 | KRAS (0.51) | GBA1KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | SMARCA2 975/4885SMARCA4 1492/4885PBRM1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.